Browse > Article
http://dx.doi.org/10.15324/kjcls.2018.50.3.337

Silymarin Attenuates Invasion and Migration through the Regulation of Epithelial-mesenchymal Transition in Huh7 Cells  

Kim, Do-Hoon (Department of Clinical Laboratory Science, Dong-Eui University)
Park, So-Jeong (Department of Clinical Laboratory Science, Dong-Eui University)
Lee, Seung-Yeon (Department of Clinical Laboratory Science, Dong-Eui University)
Yoon, Hyun-Seo (Department of Dental Hygiene, Dong-Eui University)
Park, Chung Mu (Department of Clinical Laboratory Science, Dong-Eui University)
Publication Information
Korean Journal of Clinical Laboratory Science / v.50, no.3, 2018 , pp. 337-344 More about this Journal
Abstract
Hepatocellular carcinoma (HCC), a major type of hepatoma, is associated with high recurrence and mortality because of its uncontrolled metastatic feature. Silymarin is a polyphenolic flavonoid from Silybum marianun (milk thistle) and exhibits anti-carcinogenic activity through modulation of the epithelial-mesenchymal transition (EMT) in several cancer cells. In this study, the inhibitory mechanism of silymarin against migration and invasion was investigated in the Huh7 HCC cell line. Wound healing and in vitro invasion assays were conducted to examine the effects of silymarin on migration and invasion. Western blot analysis was also applied to evaluate the inhibitory effects of silymarin on the EMT-related genes and their upstream signaling molecules. Silymarin inhibited the migratory and invasive activities of Huh7 cells. In addition, silymarin attenuated the protein expression levels of vimentin and matrix metalloproteinase (MMP)-9 as well as their transcription factors, Snail, and nuclear factor $(NF)-{\kappa}B$, while the expression of E-cadherin was increased by the silymarin treatment. Among the upstream signaling molecules, the phosphorylation of Akt was inhibited by the silymarin treatment, which was confirmed by the selective inhibitor, LY294002. Consequently, silymarin inhibited the invasive and migratory activities in Huh7 cells through the modulation of EMT-related gene expression by the PI3K/Akt signaling pathway, which may have potential as a chemopreventive agent against HCC metastasis.
Keywords
Epithelial-mesenchymal transition; NF-kappa B; Silymarin; Snail family transcription factors;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, et al. Silibinin inhibits $\beta$-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal. 2013;25:2625-2633.   DOI
2 Hsieh MJ, Lin CW, Yang SF, Chen MK, Chiou HL. Glabridin inhibits migration and invasion by transcriptional inhibition of matrix metalloproteinase 9 through modulation of NF-${\kappa}B$ and AP-1 activity in human liver cancer cells. Br J Pharmacol. 2014; 171:3037-3050.   DOI
3 Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39: 305-318.   DOI
4 Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, et al. Association of vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene. 2004;23:298-302.   DOI
5 Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007;67:2497-2507.   DOI
6 National Cancer Information Center (KR). Cancer statistics. Cancer incidence in 2015 [Internet]. Goyang: National Cancer Information Center; 2015 [Cited 2018 June 04]. Available from: https://www.cancer.go.kr/lay1/S1T639C641/contents.do.
7 National Cancer Information Center (KR). Cancer statistics. Liver cancer incidence by histology group in 2015 [Internet]. Goyang: National Cancer Information Center; 2015 [Cited 2018 June 04]. Available from: https://www.cancer.go.kr/lay1/program/S1T211C216/cancer/view.do?cancer_ seq=3317&menu_seq=3322.
8 Tang ZY. Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol. 2001;7:445-454.   DOI
9 Lee HS, Choi GH, Hwang HK, Kang CM, Choi JS, Lee WJ. The risk factors for extrahepatic recurrence after curative resection of hepatocellular carcinoma. Ann Hepatobiliary Pancreat Surg. 2010;14:227-234.
10 Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229-235.   DOI
11 Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;16:704-715.
12 Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, Foidart JM, et al. 1999. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci. 1999;112:4615-4625.
13 Huang C, Jacobson K, Schaller, MD. A role for jnk-paxillin signaling in cell migration. Cell Cycle. 2004;3:4-6.
14 Huang C, Jacobson K, Schaller MD. Map kinases and cell migration. J Cell Sci. 2004;117(Pt 20):4619-4628.   DOI
15 Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC, Lu KH. Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis. 2007;28:977-987.
16 Lee SO, Jeong YJ, Im HG, Kim CH, Chang YC, Lee IS. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun. 2007; 354:165-171.   DOI
17 Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15:178-196.   DOI
18 Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429-1437.   DOI
19 Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139:871-890.   DOI
20 van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol. 2009;5:1169-1179.   DOI
21 Kim SM, Han JH, Park SM. The role of epithelial-mesenchymal transition in the gastroenterology. Kor J Gastroenterol. 2010; 56:69-77.   DOI
22 Chen PN, Hsieh YS, Chiou HL Chu SC. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact. 2005;156:141-150.   DOI
23 Cufi S, Bonavia R, Vazquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cuyas E, et al. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food Chem Toxicol. 2013;60:360-368.   DOI
24 Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010;29:447-463.   DOI
25 Deep G, Gangar SC, Agarwal C, Agarwal R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila). 2011;4:1222-1232.   DOI
26 Skottova N, Krecman V, Simanek V. Activities of silymarin and its flavonolignans upon low density lipoprotein oxidizability in vitro. Phytother Res. 1999;13:535-537.   DOI